The number of patients with nonischemic cardiomyopathy (NICM) undergoing catheter ablation of ventricular tachycardia (VT) has increased by the years, however, there are no randomized studies of VT ablation in this population. Many studies have reported more mixed or inferior outcome after the ablation in patients with NICM as compared to in those with ischemic cardiomyopathy (ICM)-likely because of the heterogeneous VT substrates in each etiology. While, various ablation strategies for substrate modification in the setting of ICM, including low voltage area ablation, late potential abolition, and local abnormal ventricular activity elimination, have been well established, it is still unknown which ablation strategy is effective for prevention of recurrence VTs in NICM patients. Therefore, this review will highlight the recent progress made in VT ablation in patients with NICM. Apart from beta-blockers, none of the AADs for ventricular arrhythmias has been shown to improve survival; amiodarone, although being the most effective AAD for preventing VT and reducing arrhythmic death, 2 doesn't reduce the all-cause mortality, 3 likely because of its long-term side effects counterbalancing its benefits.
| INTRODUCTION
Ventricular tachycardias (VTs) increase mortality in patients with a structure heart disease. 1 To manage the VTs in this population, there are three feasible options: antiarrhythmic drugs (AADs), implantable cardioverter-defibrillator (ICD), and catheter ablation (CA).
Apart from beta-blockers, none of the AADs for ventricular arrhythmias has been shown to improve survival; amiodarone, although being the most effective AAD for preventing VT and reducing arrhythmic death, 2 doesn't reduce the all-cause mortality, 3 likely because of its long-term side effects counterbalancing its benefits. 4 Implantable cardioverter-defibrillator is the mainstay of the VTs therapy in those patients who are at risk of sudden cardiac death: however, while the benefit of ICDs in patients with ischemic cardiomyopathies (ICMs) has been well described, [4] [5] [6] no randomized trials have yet clarified their beneficial role in nonischemic cardiomyopathies (NICMs). 7, 8 Catheter ablation has emerged as an effective option for treating recurrent VTs 9,10 and a recent multicenter study has demonstrated the benefit of a successful ablation in preventing VT recurrences and prolonging the survival. 11 In patients with ICMs, a randomized control trail has reported that the rate of a composite outcome (death, VT storm and appropriate ICD shocks) was significantly lower among the patients undergoing catheter ablation than among those receiving an escalated antiarrhythmic drug therapy 12 ; furthermore, in the setting of ICMs, various ablation strategies for substrate modification including low voltage area ablation, late potential (LP) abolition and local abnormal ventricular activity (LAVA) elimination have been well established. 13, 14 On the other hand, there are no randomized studies of catheter ablation of VT in NICM patients. Many studies have reported more mixed or inferior outcome after the ablation in patients with NICM as compared to in those with ICM [15] [16] [17] -likely because of the heterogeneous VT substrates in each etiology and different VT ablation strategies.
| PREPROCEDURAL CONSIDERATION

| VT morphology
The preprocedural analysis of the VT morphology is an indispensable tool for planning the ablation and increase the probability of success. 20 We reported the correlation between VT morphology and scar area in NICM patients 21 : in this study, where patients were classified into two groups (anteroseptal or inferolateral scar type) according to the endocardial unipolar voltage, the left inferior VT axis was predictive of an anteroseptal scar (positive predictive value: 100%) and the right superior axis for inferolateral ones (positive predictive value: 89%).
If the clinical VT morphology in a 12-lead ECG should not be available due to appropriate ICD interventions, we recommend to perform a noninvasive program stimulation (NIPS) or an electrophysiological study (induction of VT) before the ablation, to check the inducibility and VT morphology.
| Baseline ECG
On the other hand, the VT is not always inducible before the procedure and its morphology can't be obtained: in these cases, the baseline ECG-its characteristics are well correlated with the unipolar low-voltage distribution in high-density endo-epicardial maps-might be helpful to predict the arrhythmogenic substrate. Oloriz et al 22 reported that the conduction disturbance with an atrioventricular block, left bundle branch block and widened QRS was associated with an anteroseptal scar in the endocardium, whereas the low QRS voltage in the limb leads was correlated with voltage abnormalities in the inferolateral area in the epicardium.
| Magnetic resonance imaging
Ventricular tachycardia ablation in patients with NICMs is considered to be challenging partly because of the frequent intramural and subepicardial location of the arrhythmogenic substrate, which can often be identified by a magnetic resonance imaging (MRI) scan that may thus have important clinical implications for preprocedural planning and intraprocedural substrate identification. 23 Piers et al 24 used contrast-enhanced MRI to describe two typical scar patterns (anteroseptal and inferolateral), accounting for 89% of the arrhythmogenic substrates in patients with NICM. Anteroseptal scars are approached from the endocardium, whereas inferolateral scars frequently require an epicardial approach.
| Computed tomography
While MRI is the gold standard for identifying myocardial scars, it is often not feasible in patients with an ICD, for which a safe alternative could be the multidetector computed tomography (CT).
Delayed enhancement cardiac CT can provide a 3D description of the structural substrate at the VT origin, together with a detailed heart anatomy. Preprocedural cardiac CT imaging offers important clues in the planning of VT ablations ( Figure 1 Out of them, 263 cases (50%) required an epicardial access, chosen after weighting several factors (Figure 2A ).
| Etiology
As it is well known that patients with postmyocarditis or arrhythmogenic right ventricular dysplasia (ARVD) are often characterized by epicardial substrates, the epicardial access could be considered as a first-line approach. In our experience, 88% of the patients with postmyocarditis and 70% of those with ARVD underwent an epicardial access.
In the setting of IDCM, the need for a first-line epicardial access has yet to be clarified.
As the previous study on VT mapping showed, scars are often more extended in the epicardium than in the endocardium, and an epicardial ablation is likely to improve the ablation success rate 28 ; however, as we reported recently, it might be reasonable to attempt the epicardial approach only when a free wall location of the scar was be expected. 
| MRI
Magnetic resonance imaging is a good tool to guide the decision to a first-line epicardial approach, because it can easily identify the epicardial extension of the scarred tissue. 29 If patients have no implanted device, MRI is recommended before procedure.
| ECG
Ventricular tachycardia morphology can be an important clue to identify which patients are likely to benefit from an epicardial approach. 30 The previous study importantly suggested that the presence of a q wave in lead I, create a high degree of suspicion for a probable epicardial location in the setting of NICM. 31 In patients with ARVD, while the presence of a QS pattern in lead V1-V3 is predictive of an epicardial RV-VT, QS pattern in the inferior leads is common in the patients with an epicardial superior axis RV VT.
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The 12-lead ECG of the baseline rhythm, particularly when there is a contraindication to the MRI or the VT morphology is not available, may also help to exclude the possible epicardial origin of the VT and avoid the epicardial access. 
| Electroanatomical findings during ablation
Besides a history of a previously failed endocardial procedure, electroanatomical findings during procedure-such as the absence of LP and low voltage area in the endocardium-provide good reasons to resort to the epicardial access. Additionally, when the unipolar penumbra area, defined as the unipolar scar beyond the bipolar low voltage area, is observed in the endocardium, 33 the epicardial mapping can be rewarding. 34, 35 Recently, Gökoglan demonstrated the superiority of the end-epicardial ablation (scar homogenization) over the standard ablation (the epicardial mapping/ablation was performed in patients for whom either the VT was inducible after the endocardial ablation or there was no endocardial scar) in patients with dilated NICMs and VT. 15 In the study, after a single procedure and with a mean follow-up period of 14 ± 2 months, the freedom from any ventricular arrhythmia in the scar homogenization group was 64%, compared with 39% in the standard ablation cohort; consequently, the epicardial ablation might be indicated for this population. On the other hand, a European multicenter study reported that the complication rate related to the | 349 epicardial access was not low, even in high experienced centers. 36 For the above-mentioned reasons, the authors suggest that we should carefully evaluate the indication to an epicardial access with a patient-by-patient approach.
| MAPPIN G AND ABLATION
The procedures are performed under general anesthesia. Since the stability of the catheter and the quality of the contact depend on the anatomy of the heart and on the site of the ablation, the standard approach in our center involves a double access (retrograde transaortic and antegrade transseptal approach), allowing for a more flexible ablation strategy.
If a first-line combined epicardial and endocardial mapping approach is undertaken, the epicardial puncture and mapping are performed before transseptal puncture.
What follows is a summary of our VT ablation workflow:
1. Activation mapping and substrate ablation: 
| CONSID ERATIONS BY EACH ETIOLOGY
We believe it is important to consider practical ablation strategies according to each etiology.
| IDCM
Idiopathic dilated cardiomyopathy is the most common etiology among NICM patients, accounting for about 50% of our whole population undergoing a VT ablation (Figures 3 and 4) .
However, when compared to ICM patients, several studies have suggested unsatisfying long-term outcomes after the ablation, 16, 17, 28, 37, 38 probably because of the less defined arrhythmia substrate (patchy or diffuse microscarring process) and the frequent intramural or subepicardial location. 
| ARVD
In ARVDs, the arrhythmogenic substrate often involves the perivalvular area (the tricuspid annulus and pulmonic valve annulus), mainly at the right ventricular free wall, while the apex are typically spared 42 ; in this setting, epicardial ablations are more frequently required compared with patients with ICMs. 43 In ARVD patients undergoing catheter ablation, the freedom from VT recurrence is generally good during long-term follow-up. 
| Postmyocarditis
Postmyocarditis seems to be characterized by an arrhythmogenic substrate set predominantly in the epicardium. 45 The previous study reported how 23 patients with postmyocarditis (88% of the study population) required an epicardial ablation, and that catheter ablation was a safe and effective solution in the short term (77% of the patients remained free of VT recurrences during the 2 year follow-up period). 46 Due to the lateral LV wall localization of the arrhythmogenic substrate, the epicardial ablations were frequently limited by the presence of the coronary arteries and phrenic nerve; 19% of the patients required their phrenic nerve to be displaced with a valvuloplasty balloon, allowing to complete the LP abolition in the majority of the cases ( Figure 6 ). However, the proximity of a coronary artery to the ablation site remains an unresolved issue.
| Valve heart disease
Sustained VTs can occur any time after undergoing after a valve surgery. Eckart et al 47 reported that periannular scars were frequently observed in patients with VT developed after the valve repair.
Although the main challenge when dealing with this population is the limited LV accessibility, hindered by the mechanical prosthetic valve, Soejima et al 48 described the feasibility of the epicardial ablation in patients who had previously undergone an aortic and mitral valve mechanical repair; all patients presented abnormally low voltage areas with fractionated or delayed isolated potentials on the apical epicardium, and a microscopic pathological evaluation of the resected tissue of two patients revealed more dense fibrosis on the epicardium than the endocardium. These findings may allow the option of an ablation strategy based on the epicardial access only to be considered even in case of previous mechanical prosthetic valve surgery.
| Hypertrophic cardiomyopathy
In patients with hypertrophic cardiomyopathies (HCMs), the occurrence of monomorphic VTs is rare. Dukkipati et al 49 studied 10 such patients, identifying an epicardial scar in 8 of them (80%) and an endocardial scar in 6 (60%); 78% of the patients remained free from VT recurrences during the follow-up period (median of about 3 years).
| Lamin A/C cardiomyopathy
About 10% of the DCM patients present pathogenic genetic mutations in proteins encoded by the Lamin A/C (LMNA) gene. This autosomal dominant heart disease is generally more severe than other kind of DCMs, and it's characterized by a progressive conduction system impairment and a high risk of life-threatening ventricular arrhythmias. 50 The arrhythmogenic substrate in patients with the LMNA mutation is usually represented by an intramural and/or basal perivalvular scar, which probably explains why performing a catheter ablation in this setting is particularly challenging and less effective. 
| Cardiac sarcoidosis
Cardiac sarcoidosis is usually characterized by a severe progressive heart failure, conduction system disorders and malignant ventricular arrhythmias; unfortunately, CA in these patients is burdened by a Although randomized trials will be necessary to confirm these findings, such a large-scale study surely encourage us to consider the ablation of VT more feasible option in the setting of NICMs.
Our group previously reported that a combined endpoint of LP abolition and VT noninducibility was effective to increase the longterm arrhythmia-free survival in patients with ICM 13 ; on the other hand, it is still unknown whether such benefit extends also to patients with NICM.
In our experience, comprising 403 patients with NICMs, the with DCMs, 79% in case of myocarditis, 86% for ARVDs, 68% in presence of a valvular heart disease and 72% in the remaining etiologies. We concluded that, even for patients with NICMs, the strategy of LP abolition and noninducibility could bear positive results in the long term. However, we again strongly recommend to plan the ablation according to the particular characteristics of every single patient, as the blind application of general criteria might prove misleading.
| NEW TOOLS FOR VT ABLATION
A new multipolar grid mapping catheter 54 has recently been made available and, being able to create different voltage/activation maps considering the bipolar electrograms from orthogonal wavefront direction relative to the electrodes orientation, it might be useful for mapping the ventricle.
We have been investigating the impact of a bipolar ablation to treat VTs with a septal substrate, approached with two ablation catheters opposing each other across the septum to create a transmural lesion (Figure 7 ). 55 For intramural lesion, irrigated needle ablations might be of future help. 56 
| CONCLUSION
As the number of VT ablations in patients with NICMs is rising, it is more than ever necessary to identify the best strategy to treat this population. To attain this goal, however, further studies are necessary.
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